Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome
A systematic review and meta-analysis
- Rita S. Suri, MD1,
- William F. Clark, MD1,
- Nick Barrowman, PHD2,
- Jeffrey L. Mahon, MD, MSC34,
- Heather R. Thiessen-Philbrook, MMATH1,
- M. Patricia Rosas-Arellano, MD, PHD1,
- Kelly Zarnke, MD, MSC35,
- Jocelyn S. Garland, MD6 and
- Amit X. Garg, MD, MA, PHD13
- 1Division of Nephrology, London Health Sciences Center, University of Western Ontario, London, Canada
- 2Chalmers Research Group, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada
- 3Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada
- 4Division of Endocrinology, London Health Sciences Center, University of Western Ontario, London, Canada
- 5Department of Medicine, London Health Sciences Center, University of Western Ontario, London, Canada
- 6Division of Nephrology, Kingston General Hospital, Queen’s University, Kingston, Canada
- Address correspondence and reprint requests to Rita Suri, MD, FRCPC, FACP, Kidney Clinical Research Unit, London Health Sciences Center, Room ELL-111 Victoria Hospital, 800 Commissioners Rd. East, London, Ontario, Canada N6A 4G5. E-mail: rita.suri{at}lhsc.on.ca
Abstract
OBJECTIVE—To quantify the incidence of diabetes during the acute phase of diarrhea-associated hemolytic uremic syndrome (D+HUS) and to identify features associated with its development.
RESEARCH DESIGN AND METHODS—A systematic review and meta-analysis of articles assessing diabetes during D+HUS was conducted. Relevant citations were identified from Medline, Embase, and Institute for Scientific Information Citation Index databases. Bibliographies of relevant articles were hand searched. All articles were independently reviewed for inclusion and data abstraction by two authors.
RESULTS—Twenty-one studies from six countries were included. Only 2 studies reported a standard definition of diabetes; 14 defined diabetes as hyperglycemia requiring insulin. The incidence of diabetes during the acute phase of D+HUS could be quantified in a subset of 1,139 children from 13 studies (1966–1998, age 0.2–16 years) and ranged from 0 to 15%, with a pooled incidence of 3.2% (95% CI 1.3–5.1, random-effects model, significant heterogeneity among studies, P = 0.007). Children who developed diabetes were more likely to have severe disease (e.g., presence of coma or seizures, need for dialysis) and had higher mortality than those without diabetes. Twenty-three percent of those who developed diabetes acutely died, and 38% of survivors required long-term insulin (median follow-up 12 months). Recurrence of diabetes was possible up to 60 months after initial recovery.
CONCLUSIONS—Children with D+HUS should be observed for diabetes during their acute illness. Consideration should be given to long-term screening of D+HUS survivors for diabetes.
Footnotes
-
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
- DIABETES CARE
